Zacks: Analysts Anticipate Evoke Pharma, Inc. (EVOK) to Announce -$0.15 Earnings Per Share
Equities research analysts expect Evoke Pharma, Inc. (NASDAQ:EVOK) to report earnings per share (EPS) of ($0.15) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Evoke Pharma’s earnings. Evoke Pharma posted earnings of ($0.24) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 37.5%. The company is expected to report its next earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Evoke Pharma will report full year earnings of ($0.74) per share for the current financial year. For the next financial year, analysts anticipate that the company will report earnings of ($0.48) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.15. During the same period in the previous year, the company posted ($0.41) earnings per share.
Several equities research analysts have recently weighed in on EVOK shares. FBR & Co reiterated a “buy” rating and issued a $9.00 price target on shares of Evoke Pharma in a report on Thursday, May 18th. ValuEngine cut Evoke Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, HC Wainwright set a $9.00 price objective on Evoke Pharma and gave the stock a “buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Evoke Pharma currently has a consensus rating of “Hold” and a consensus target price of $7.25.
Hedge funds have recently bought and sold shares of the company. State Treasurer State of Michigan boosted its stake in Evoke Pharma by 62.2% in the first quarter. State Treasurer State of Michigan now owns 291,966 shares of the specialty pharmaceutical company’s stock worth $905,000 after buying an additional 111,966 shares during the last quarter. Vanguard Group Inc. boosted its stake in Evoke Pharma by 15.1% in the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after buying an additional 68,544 shares during the last quarter. Finally, Sphera Funds Management LTD. acquired a new stake in Evoke Pharma during the first quarter worth $1,550,000. 12.37% of the stock is owned by hedge funds and other institutional investors.
Shares of Evoke Pharma (NASDAQ:EVOK) opened at 2.58 on Thursday. Evoke Pharma has a 52-week low of $1.35 and a 52-week high of $4.55. The company’s 50 day moving average price is $2.44 and its 200 day moving average price is $2.72. The company’s market capitalization is $39.70 million.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.